IMAB - התחייבויות לטווח ארוך להון I-Mab Biopharma

The market trend for I-Mab (IMAB) demonstrates a long-term debt-to-equity ratio of 0.01. The biotech's business relies on the complete liquidation of its Chinese units, which has eliminated US-China trade conflicts. Patent protection of the IT platform limits competition despite strict FDA oversight. The company's environmental strategy is based on modernizing filtration systems and reducing the carbon footprint of its transportation.

Amid market uncertainty, it is critical for investors to assess the resilience of I-Mab (IMAB) financing structure relative to long-term liabilities. Reliance on licensing agreements with pharma behemoths reduces credit risks, while the ratio of long-term loans to equity on this chart reflects the share of borrowed funds (exceeding one year) in the total enterprise value, where a decline in this metric confirms financial autonomy and minimizes the probability of portfolio default.